Skull Marrow Drives Brain Inflammation After Injury
A study of 41 participants and a randomized trial link aging, cranial bone marrow activity, and cognition in chronic traumatic brain injury.
Updated on Nov. 6, 2026 in Alzheimer’s
Cranial bone marrow myelopoiesis is enhanced in patients older than 65 with chronic traumatic brain injury, according to a study of 41 participants. A randomized controlled trial of 40 older patients found that fenofibrate, a PPARα agonist, improved cognition and reversed biomarkers of the condition.
Why it matters
The findings point to bone marrow-derived immune cells in the skull as a possible contributor to brain inflammation after injury in older adults. A drug already in use suggests a potential route to treatment that targets this pathway.
The bone marrow analysis covered 41 participants, with older patients over 65 compared against younger patients aged 18 to 45 and healthy controls. The randomized trial enrolled 40 older participants, and the extraction does not report the full effect sizes or whether all findings were confirmed in larger cohorts.
The players
Science
Science is a leading peer-reviewed scientific journal published by the American Association for the Advancement of Science, known for publishing high-impact research across many disciplines.
The details
Researchers used single-cell RNA sequencing on cranial bone marrow cells from older patients with chronic traumatic brain injury and found an increased inflammatory signature. In aged mice, bone marrow-derived myeloid cells were shown to infiltrate the brain, and the effect depended on interleukin-1β, while fenofibrate reduced inflammatory monocyte differentiation.
Timeline
The study was published on November 6, 2026, in Science.
Health Landscape
Fenofibrate has long been prescribed to manage cholesterol and triglycerides through its PPARα activity. This study tests whether that same pathway can be targeted to reduce brain inflammation and improve cognition in older adults with chronic traumatic brain injury.
For older adults with a history of brain injury, the findings suggest that inflammation driven by bone marrow cells may be a factor in cognitive decline. Any clinical use of fenofibrate for this purpose would require further trials before changing treatment decisions.
The takeaway
Older adults with a history of traumatic brain injury may benefit from attention to inflammation, and ongoing trials will show whether targeting the PPARα pathway with fenofibrate can translate into lasting cognitive gains.
Further reading
Explore more research on Alzheimer’s and related neurological conditions.
Source note: This article includes information reported by Science.
